Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
Dublin, Feb. 28, 2025 (GLOBE NEWSWIRE) -- The "Neurofibromatoses: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This reports provides a data-driven overview of the
BioInvent International AB: Year-End Report January 1 - December 31, 2024
02:30am, Thursday, 27'th Feb 2025
LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical program
AstraZeneca gets £2bn boost from breast cancer drug readout
08:51am, Wednesday, 26'th Feb 2025
AstraZeneca PLC (LSE:AZN) has seen £2 billion added to its market value after reporting positive results from a breast cancer drug trial. The experimental treatment, camizestrant, improved patient
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-depen
AstraZeneca therapy improves survival in late-stage breast cancer trial
02:19am, Wednesday, 26'th Feb 2025
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting wors
Final Trades: Starbucks, Astrazeneca, Western Union and the IYR
01:20pm, Tuesday, 25'th Feb 2025
The Investment Committee give you their top stocks to watch for the second half.
Investors can contact the law firm at no cost to learn more about recovering their losses
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
04:00am, Monday, 24'th Feb 2025
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pionee
3 Magnificent Growth Stocks to Buy Right Now
05:47am, Saturday, 22'nd Feb 2025
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy increase in value.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN
04:15pm, Friday, 21'st Feb 2025
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities la
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities la
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are a
Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN
07:30am, Friday, 21'st Feb 2025
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities la
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against As
